{
    "eid": "2-s2.0-85104420022",
    "title": "Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial",
    "cover-date": "2021-08-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Surgery",
            "@code": "2746",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "Biosimilar",
        "Combination therapy",
        "Efficacy",
        "Metastatic breast cancer",
        "Monotherapy",
        "Safety",
        "Trastuzumab"
    ],
    "authors": [
        "Hope S. Rugo",
        "Eduardo J. Pennella",
        "Unmesh Gopalakrishnan",
        "Miguel Hernandez-Bronchud",
        "Jay Herson",
        "Hans Friedrich Koch",
        "Subramanian Loganathan",
        "Sarika Deodhar",
        "Ashwani Marwah",
        "Alexey Manikhas",
        "Igor Bondarenko",
        "Joseph D. Parra",
        "Maria Luisa T. Abesamis-Tiambeng",
        "Charuwan Akewanlop",
        "Ihor Vynnychenko",
        "Virote Sriuranpong",
        "Sirshendu Roy",
        "Eduardo Patricio Yanez Ruiz",
        "Abhijit Barve",
        "Cornelius F. Waller"
    ],
    "citedby-count": 2,
    "ref-count": 28,
    "ref-list": [
        "Targeted therapy of cancer: new prospects for antibodies and immunoconjugates",
        "Monoclonal antibodies in gynecological cancer: a critical point of view",
        "A clinician's guide to biosimilars in oncology",
        "Barriers to the access and use of rituximab in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia: a physician survey",
        "Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: a physician survey in the United States and emerging markets",
        "Worldwide experience with biosimilar development",
        "Epidemiology of breast cancer",
        "For the Central European Cooperative Oncology Group (CECOG). Third consensus on medical treatment of metastatic breast cancer",
        "GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012",
        "Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications",
        "Monoclonal antibodies and Fc fragments for treating solid tumors",
        "Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831",
        "Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer",
        "Adjuvant trastuzumab in HER2-positive breast cancer",
        "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2",
        "FDA approves first biosimilar for the treatment of certain breast and stomach cancers",
        "A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab",
        "A bioequivalence study for Hercules, a biosimilar trastuzumab candidate in development. Poster presented at Pharmacology",
        "Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)-positive metastatic breast cancer: a randomized clinical trial",
        "Study of efficacy and safety of MYL-1401O + taxane vs Herceptin\u00a9 + taxane for 1st line",
        "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)",
        "Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer",
        "Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study",
        "Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial",
        "Therapeutic strategies for human epidermal receptor-2 positive metastatic breast cancer: a literature review"
    ],
    "affiliation": [
        {
            "affiliation-city": "Canonsburg",
            "@id": "60274569",
            "affilname": "Viatris, Inc.",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60274569",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60199575",
            "affilname": "Siriraj Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Quezon City",
            "@id": "60071484",
            "affilname": "St. Luke's Medical Center Quezon City",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071484",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Dnipro",
            "@id": "60070090",
            "affilname": "Dnipro State Medical University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60070090",
            "affiliation-country": "Ukraine"
        },
        {
            "affiliation-city": "San Francisco",
            "@id": "60029881",
            "affilname": "UCSF Helen Diller Family Comprehensive Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60029881",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Freiburg im Breisgau",
            "@id": "60024805",
            "affilname": "Universit\u00e4tsklinikum Freiburg",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60024805",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Sumy",
            "@id": "60016511",
            "affilname": "Sumy State University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016511",
            "affiliation-country": "Ukraine"
        },
        {
            "affiliation-city": "Temuco",
            "@id": "60012035",
            "affilname": "Universidad de la Frontera",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012035",
            "affiliation-country": "Chile"
        },
        {
            "affiliation-city": "Baltimore",
            "@id": "60006183",
            "affilname": "Johns Hopkins Bloomberg School of Public Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006183",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Saint Petersburg",
            "@id": "126644584",
            "affilname": "City Clinical Oncology Dispensary",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/126644584",
            "affiliation-country": "Russian Federation"
        },
        {
            "affiliation-city": "San Juan City",
            "@id": "126186367",
            "affilname": "Cardinal Santos Medical Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/126186367",
            "affiliation-country": "Philippines"
        },
        {
            "affiliation-city": "Bengaluru",
            "@id": "126068680",
            "affilname": "Biocon Biologics India Limited",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/126068680",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Nasik",
            "@id": "123351617",
            "affilname": "Curie Manavata Cancer Centre",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/123351617",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Barcelona",
            "@id": "120952129",
            "affilname": "GenesisCare Corachan Institute of Oncology",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/120952129",
            "affiliation-country": "Spain"
        }
    ],
    "funding": [
        "Viatris Inc",
        "Biocon Limited"
    ]
}